The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 5, 2000, Pages 589-594

  Piccini, Paola ^a   Brooks, David J ^a   Korpela, Kirsi ^b   Pavese, Nicola ^a   Karlsson, Marianne ^b   Gordin, Ariel ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ORION CORPORATION   (Finland)

Author keywords

Controlled release levodopa; Entacapone; Parkinson's disease

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034058782     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.5.589     Document Type: Article

References (38)

1. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;i:345-9.
2. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-509.
3. Fabbrini G, Juncos J, Mouradian M, et al. Levodopa pharmacokinetics and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-6.
4. Pahwa R, Lyons K, McGuire D, et al. Comparison of standard carbidopa-levodopa and sustained-release carbidopa levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord 1997;12:677-81.
5. Hutton J, Morris J. Therapeutic advantages of sustained release levodopa formulations. CNS Drugs 1994;2:110-19.
6. Koller W, Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology 1994; 44(suppl 6):S23-8.
7. LeWitt P. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. Neurology 1992;42(suppl 1):29-32.
8. Graham J, Henderson J, Morris J, et al. Comparison of standard Madopar and controlled release Madopar in Parkinson's disease. Aust NZ J Med 1991;21:11-15.
9. Yeh KC, August TF, Bush DF, et al. Pharmacokitetics and bioavailability of Sinemet CR™: a summary of human studies. Neurology 1989;39:25-38.
10. Marion MH, Stocchi F, Malcolm SL, et al. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. European Neurology 1994;27(suppl 1):54-8.
11. Nissinen E, Linden IB, Schultz E, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmieddberg's Archives of Pharmacology 1992;346: 262-6.
12. Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 1992;587:241-9.
13. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56.
14. Myllylä VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993;45:419-23.
15. Kaakkola S, Teräväinen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
16. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyl transferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychyiatry 1994;57:186-9.
17. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyl transferase inhibition, on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-19.
18. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-96.
19. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-33.
20. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month's double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
21. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in Parkinson patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51: 1309-14.
22. Cedarbaum JM, Lyn Breck RN, Kutt H, et al. Controlled-release levodopa/carbidopa. II Sinemet CR™4 treatment of response fluctuations in Parkinson's disease. Neurology 1987;37:1607-12.
23. Kaakkpla S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa-carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995;2:341-7.
24. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Farm S, Marsden CD, Calne D, et al, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park: Macmillan Helthcare Information, 1987:153-63.
25. Esteguy M., Bonnet AM, Kefalos J, et al. Le test a la L-Dopa dans la maldie de Parkinson. Rev Neurol (Paris) 1985:141: 413-415.
26. Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 1991;9:167-76.
27. Karlsson M, Wikberg T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 1992;10:593-600.
28. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Marcel Dekker, New York, 1982.
29. 18F-6-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44:1292-7.
30. Ruottinen HM, Rinne JO, Ruotsalainen UH, et al. Striatal F-fluorodopa utilisation after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sea 1995;10:91-106.
31. Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 1996;16:854-63.
32. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
33. Jorga K, Fotteler B, Schmitt M, et al. Effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa-benserazide formulations. Eur Neurol 1997;38:59-67.
34. Friedhoff AJ, Bonnet K, Rosengarten H. Reversal of two manifestations of dopamine receptor supersensitivity by administration of levodopa. Research Communications in Chemical Patology and Pharmacology 1977;16:411-23.
35. Reches A, Wagner HR, Jackson-Lewis V, et al. Chronic levodopa or pergolide administration induces down regulation of dopamine receptors in denervated striatum. Neurology 1994;34:1208-12.
36. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-92.
37. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-23.
38. Brannan T, Martinez-Tica J, Yahr MD. Effect of long term L-dopa administration on striatal extracellular dopamine release. Neurology 1981;41:2596-8.